S&P 500   4,516.57 (-1.32%)
DOW   34,422.88 (-0.63%)
QQQ   380.67 (-2.37%)
AAPL   160.30 (-2.11%)
MSFT   318.75 (-3.26%)
FB   304.78 (-1.81%)
GOOGL   2,820.54 (-1.36%)
AMZN   3,359.16 (-2.28%)
TSLA   1,020.58 (-5.90%)
NVDA   303.82 (-5.43%)
BABA   112.67 (-7.65%)
NIO   31.99 (-11.63%)
CGC   9.98 (-3.67%)
AMD   142.07 (-5.71%)
GE   92.36 (-3.01%)
MU   80.95 (-2.33%)
T   23.43 (+1.65%)
F   19.08 (-3.98%)
DIS   144.96 (-1.52%)
PFE   54.11 (+2.02%)
AMC   27.07 (-10.60%)
ACB   5.78 (-5.86%)
BA   196.58 (-2.87%)
S&P 500   4,516.57 (-1.32%)
DOW   34,422.88 (-0.63%)
QQQ   380.67 (-2.37%)
AAPL   160.30 (-2.11%)
MSFT   318.75 (-3.26%)
FB   304.78 (-1.81%)
GOOGL   2,820.54 (-1.36%)
AMZN   3,359.16 (-2.28%)
TSLA   1,020.58 (-5.90%)
NVDA   303.82 (-5.43%)
BABA   112.67 (-7.65%)
NIO   31.99 (-11.63%)
CGC   9.98 (-3.67%)
AMD   142.07 (-5.71%)
GE   92.36 (-3.01%)
MU   80.95 (-2.33%)
T   23.43 (+1.65%)
F   19.08 (-3.98%)
DIS   144.96 (-1.52%)
PFE   54.11 (+2.02%)
AMC   27.07 (-10.60%)
ACB   5.78 (-5.86%)
BA   196.58 (-2.87%)
S&P 500   4,516.57 (-1.32%)
DOW   34,422.88 (-0.63%)
QQQ   380.67 (-2.37%)
AAPL   160.30 (-2.11%)
MSFT   318.75 (-3.26%)
FB   304.78 (-1.81%)
GOOGL   2,820.54 (-1.36%)
AMZN   3,359.16 (-2.28%)
TSLA   1,020.58 (-5.90%)
NVDA   303.82 (-5.43%)
BABA   112.67 (-7.65%)
NIO   31.99 (-11.63%)
CGC   9.98 (-3.67%)
AMD   142.07 (-5.71%)
GE   92.36 (-3.01%)
MU   80.95 (-2.33%)
T   23.43 (+1.65%)
F   19.08 (-3.98%)
DIS   144.96 (-1.52%)
PFE   54.11 (+2.02%)
AMC   27.07 (-10.60%)
ACB   5.78 (-5.86%)
BA   196.58 (-2.87%)
S&P 500   4,516.57 (-1.32%)
DOW   34,422.88 (-0.63%)
QQQ   380.67 (-2.37%)
AAPL   160.30 (-2.11%)
MSFT   318.75 (-3.26%)
FB   304.78 (-1.81%)
GOOGL   2,820.54 (-1.36%)
AMZN   3,359.16 (-2.28%)
TSLA   1,020.58 (-5.90%)
NVDA   303.82 (-5.43%)
BABA   112.67 (-7.65%)
NIO   31.99 (-11.63%)
CGC   9.98 (-3.67%)
AMD   142.07 (-5.71%)
GE   92.36 (-3.01%)
MU   80.95 (-2.33%)
T   23.43 (+1.65%)
F   19.08 (-3.98%)
DIS   144.96 (-1.52%)
PFE   54.11 (+2.02%)
AMC   27.07 (-10.60%)
ACB   5.78 (-5.86%)
BA   196.58 (-2.87%)
NASDAQ:HSTO

Histogen Stock Forecast, Price & News

$0.42
-0.02 (-4.41%)
(As of 12/3/2021 12:44 PM ET)
Add
Compare
Today's Range
$0.41
$0.45
50-Day Range
$0.44
$0.79
52-Week Range
$0.42
$1.98
Volume
5,402 shs
Average Volume
1.84 million shs
Market Capitalization
$17.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.89
30 days | 90 days | 365 days | Advanced Chart
Receive HSTO News and Ratings via Email

Sign-up to receive the latest news and ratings for Histogen and its competitors with MarketBeat's FREE daily newsletter.


Histogen logo

About Histogen

Histogen, Inc. engages in the development of potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. It focuses in Human Multipotent Cell Conditioned Media, Human Extracellular Matrix, and Hair Stimulating Complex. The company was founded by Steven J. Mento and Gail K. Naughton on July 13, 2005 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HSTO
Fax
N/A
Employees
19
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.06 million
Book Value
$0.46 per share

Profitability

Net Income
$-18.77 million
Net Margins
-1,018.14%
Pretax Margin
-1,021.79%

Debt

Price-To-Earnings

Miscellaneous

Free Float
37,473,000
Market Cap
$17.36 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/10/2022

MarketRank

Overall MarketRank

2.12 out of 5 stars

Medical Sector

489th out of 1,391 stocks

Pharmaceutical Preparations Industry

223rd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -












Histogen (NASDAQ:HSTO) Frequently Asked Questions

Is Histogen a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Histogen in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Histogen stock.
View analyst ratings for Histogen
or view top-rated stocks.

Are investors shorting Histogen?

Histogen saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 377,900 shares, an increase of 35.2% from the October 31st total of 279,600 shares. Based on an average daily volume of 438,300 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.9% of the company's shares are sold short.
View Histogen's Short Interest
.

When is Histogen's next earnings date?

Histogen is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Histogen
.

How were Histogen's earnings last quarter?

Histogen Inc. (NASDAQ:HSTO) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. Histogen had a negative trailing twelve-month return on equity of 84.22% and a negative net margin of 1,018.14%. During the same period in the previous year, the business earned ($0.27) EPS.
View Histogen's earnings history
.

What price target have analysts set for HSTO?

2 Wall Street analysts have issued 12 month price objectives for Histogen's stock. Their forecasts range from $2.40 to $4.00. On average, they anticipate Histogen's share price to reach $3.20 in the next twelve months. This suggests a possible upside of 669.2% from the stock's current price.
View analysts' price targets for Histogen
or view top-rated stocks among Wall Street analysts.

Who are Histogen's key executives?

Histogen's management team includes the following people:
  • Steven J. Mento, Executive Chairman, President & CEO
  • Thomas L. Hubka, Senior Director-Business Operations
  • Susan A. Knudson, Chief Financial Officer, CAO, Secretary & EVP
  • Martin Latterich, Vice President-Technical Operations
  • Moya M. Daniels, Executive VP, Head-Regulatory & Quality

What other stocks do shareholders of Histogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Histogen investors own include Carnival Co. & (CCL), Intel (INTC), Genius Brands International (GNUS), Gilead Sciences (GILD), Clovis Oncology (CLVS), B2Gold (BTG), BIOLASE (BIOL), (BBI.V) (BBI), Advanced Micro Devices (AMD) and Akers Biosciences (AKER).

What is Histogen's stock symbol?

Histogen trades on the NASDAQ under the ticker symbol "HSTO."

Who are Histogen's major shareholders?

Histogen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.50%), Newman Dignan & Sheerar Inc. (0.13%), Two Sigma Securities LLC (0.13%), Citadel Advisors LLC (0.08%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends for Histogen
.

Which major investors are selling Histogen stock?

HSTO stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC.
View insider buying and selling activity for Histogen
or view top insider-selling stocks.

Which major investors are buying Histogen stock?

HSTO stock was acquired by a variety of institutional investors in the last quarter, including Newman Dignan & Sheerar Inc., Geode Capital Management LLC, and Two Sigma Securities LLC.
View insider buying and selling activity for Histogen
or or view top insider-buying stocks.

How do I buy shares of Histogen?

Shares of HSTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Histogen's stock price today?

One share of HSTO stock can currently be purchased for approximately $0.42.

How much money does Histogen make?

Histogen has a market capitalization of $17.36 million and generates $2.06 million in revenue each year. The company earns $-18.77 million in net income (profit) each year or ($0.59) on an earnings per share basis.

How many employees does Histogen have?

Histogen employs 19 workers across the globe.

What is Histogen's official website?

The official website for Histogen is www.histogen.com.

Where are Histogen's headquarters?

How can I contact Histogen?

Histogen's mailing address is 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127. The company can be reached via phone at (858) 526-3100 or via email at [email protected].


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.